EXCELSIOR, MN – January 12, 2022 – INNOVATION PARTNERS LLC today announced the appointment of Melinda Algera, Executive Director, Market Access Strategy, and Nancy Danielson, Chief Financial Officer, in January of 2022.
Melinda Algera comes to Innovation Partners with 26 years of pharmaceutical industry experience with the past 13 years focused specifically in oncology, hematology and rare disease. Through her pervious roles at Merck, TESARO/GSK, Astellas, J&J and Cytyc/Hologic, she brings a substantial depth of experience with several oncology therapeutics used for multiple indications.
Melinda is highly skilled in product launches, strategic product positioning, contract maximization, distribution channels, reimbursement strategies and product adoption pull through. She will work across cross-functional teams leading the development of project strategy and objectives to increase market access capabilities with clients and stakeholders. Melinda holds a Master of Business Administration degree from Texas A&M – Tarleton State University Campus and a Bachelor of Science Degree in Finance/Military Science from Northern Michigan University.
Nancy Danielson comes to Innovation Partners with over 30 years of Accounting and Finance experience with both public and private companies. Previous roles include CFO, Director of Revenue Accounting, Controller and Senior Financial Analyst.
Nancy is highly skilled in the areas of finance and accounting. Nancy will work closely with the Innovation Partners team leading financial statements, forecasting and budgeting. Nancy holds a BS from Iowa State University and an MBA in Finance from the University of Minnesota and passed the CPA exam.
About INNOVATION PARTNERS
Innovation Partners, LLC (IP) is high-touch biomedical consulting company that inquires to illuminate and inform healthcare connections, to make lives better. IP serves U.S. and global manufacturers seeking access for their innovations, across the product development continuum, for patients, providers, and payers. Through influential and wide-reaching relationships, extensive experience, deep expertise, and actionable insights, IP helps biopharmaceutical, medical device, and molecular diagnostic manufacturers bring their healthcare innovations to a successful market launch and commercialization. With a focus in oncology, hematology and rare diseases, their core services and capabilities include medical affairs and education, market and payer access, and quantitative and qualitative market research. Since 2011, IP has partnered with more than 50 clients to support nearly 50 brand development and launch strategies. https://innovationpartners.org/
Contact:
Dave Melin
Founder and Managing Director
